Hematological Malignancies Clinical Trial
Official title:
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies
The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03248479 -
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05454241 -
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT06041815 -
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
|
||
| Recruiting |
NCT02300571 -
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
|
N/A | |
| Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
| Completed |
NCT00379587 -
Rituximab for Prevention of Chronic GVHD
|
Phase 1/Phase 2 | |
| Completed |
NCT01162096 -
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT00506948 -
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
|
Phase 2 | |
| Active, not recruiting |
NCT04557098 -
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT04283097 -
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
|
Phase 1 | |
| Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
| Completed |
NCT01725555 -
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Completed |
NCT00438178 -
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT03711604 -
Compassionate Use Study of Tenalisib (RP6530)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01168882 -
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT01246206 -
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
|
Phase 2 | |
| Completed |
NCT01172132 -
The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
|
N/A | |
| Completed |
NCT00506402 -
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT00163644 -
RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT
|
N/A | |
| Completed |
NCT01063647 -
Dose-range Finding Treosulfan-based Conditioning
|
Phase 1/Phase 2 |